What Exactly Is A ‘Small Biotech’? US Medicare Agency Will Try To Spell It Out
Executive Summary
CMS’s new price negotiation authority has an exemption for ‘small biotech’ companies. The agency’s implementation plan suggests that will be a tricky concept to define.
You may also be interested in...
Pharma vs The IRA — Industry Leaders React To Merck Lawsuit
Execs offer a guarded reaction, noting the need for continued dialogue, but emphasize the dire threat that the pricing program poses to the pharma business model.
Pharma vs The IRA — Industry Leaders React To Merck Lawsuit
Execs offer a guarded reaction, noting the need for continued dialogue, but note the dire threat that the pricing program poses to the pharma business model.
BIO Notebook: Sanofi Hunts For Later-Stage Assets; Orphan Drug Sponsors Hunt For Legislative Fixes
Also, Novavax looks to turn its also-ran vaccine into a contender by banking on tolerability as government support recedes and the US COVID market goes commercial.